These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 29678708)
1. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708 [TBL] [Abstract][Full Text] [Related]
2. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324 [TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902 [TBL] [Abstract][Full Text] [Related]
7. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781 [TBL] [Abstract][Full Text] [Related]
8. Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide. Foro Arnalot P; Pera O; Rodriguez N; Sanz X; Reig A; Membrive I; Ortiz A; Granados R; Algara M Clin Transl Oncol; 2017 Oct; 19(10):1225-1231. PubMed ID: 28389881 [TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233 [TBL] [Abstract][Full Text] [Related]
10. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700 [TBL] [Abstract][Full Text] [Related]
12. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550 [TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT. Sutera P; Kalash R; Flickinger J; Engh J; Heron DE Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004 [TBL] [Abstract][Full Text] [Related]
14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
15. Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. Kim N; Chang JS; Wee CW; Kim IA; Chang JH; Lee HS; Kim SH; Kang SG; Kim EH; Yoon HI; Kim JW; Hong CK; Cho J; Kim E; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Kim IH; Suh CO Strahlenther Onkol; 2020 Jan; 196(1):58-69. PubMed ID: 31489457 [TBL] [Abstract][Full Text] [Related]
16. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
17. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451 [TBL] [Abstract][Full Text] [Related]
18. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805 [TBL] [Abstract][Full Text] [Related]
19. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354 [TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]